The Ajarn Kasem Pangsriwong Foundation supported the research project;Pharmaceutical Care Training Center(PCTC)at the Faculty of Pharmacy,Chiang Mai University。
Background:The patterns of dual antiplatelet therapy(DAPT)use and the associated clinical outcomes in current practice remain limited.This study evaluates DAPT regimen patterns and clinical outcomes among acute corona...
Background: Individuals with coronary artery disease (CAD) who have undergone a percutaneous coronary intervention (PCI) are at an increased risk for adverse coronary events. Management with dual antiplatelet therapy ...
supported by the Scientific and Technological Development Plan of Jilin Province China(Grant No.20210204068YY).
Clopidogrel effectively inhibits platelet aggregation in response to ADP by irreversibly binding to the platelet P2Y_(12) receptor through its active metabolite.However,the observed discrepancies between the pharmacok...
This study was supported by the China National Key R&D Project (contract No. 2022YFC2503500);The CCC-ACS project is a program of the AHA and the CSC. The AHA received funding from Pfizer through an independent grant for learning and change and Astra-Zeneca as a quality improvement initiative.
To the Editor:Dual antiplatelet therapy(DAPT),which comprises aspirin plus a P2Y12 receptor inhibitor,is the standard approach for reducing cardiac and systemic ischemic events in individuals with coronary artery dise...
Objective:To analyze the combined therapeutic effect of clopidogrel(CLO)and aspirin(ASP)on coronary heart disease(CHD)in community-dwelling elderly.Methods:Thirty elderly patients with CHD who were admitted to the Xin...
supported by the National Natural Science Foundation of China(Grant No.82170351);the Jiangsu Province's Key Provincial Talents Program(Grant No.ZDRCA2016013);the Special Fund for Key R&D Plans(Social Development)of Jiangsu Province(Grant No.BE2019754).
Dear Editor,Cardiovascular disease is the leading cause of deaths worldwide,with coronary artery disease(CAD)accounting for approximately 50%of its mortality.Dual antiplatelet therapy,including aspirin and a P2Y12 inh...
supported by the National Natural Science Foundation of China(No.62172288).
Objective To investigate the impact of CYP2C19 gene polymorphism on clopidogrel reactivity and its association with longterm clinical outcome in patients with coronary heart disease(CHD)undergoing percutaneous coronar...
Aspirin,other antiplatelet agents,and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases.A concomitant proton pump inhibitor(PPI)treatment is often prescribed in these p...
Background Stroke after acute coronary syndrome(ACS)can be devastating.It is uncertain whether the risks of ischaemic stroke or intracranial haemorrhage(ICH)are associated with different choices of P2Y12 inhibitors(po...
Objective: to analyze the value of medical intervention on angina pectoris in cardiovascular department. Methods: 80 patients were selected from January 2019 to February 2021 for analysis within the time range of the ...